Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sitagliptin + dapagliflozin + lobeglitazone
- Development stage
- Phase 4
- Lead developer
- Yonsei University
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Sitagliptin + dapagliflozin + lobeglitazone is a triple combination therapy investigated for the management of type 2 diabetes mellitus. This regimen combines three distinct classes of glucose-lowering agents: sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor; dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor; and lobeglitazone, a thiazolidinedione (TZD). Sitagliptin works by preventing the degradation of incretin hormones, thereby enhancing glucose-dependent insulin secretion and suppressing glucagon release. Dapagliflozin promotes the renal excretion of glucose by inhibiting its reabsorption in the proximal tubule. Lobeglitazone acts as a peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist, improving insulin sensitivity in muscle, fat, and liver tissues. This combination is typically evaluated in patients who have inadequate glycemic control on standard therapies, aiming to provide comprehensive metabolic control through complementary mechanisms.
- Other names
- sitagliptin/dapagliflozin/lobeglitazone combinationSGLT2i and TZD add-on to DPP4iSGLT-2i and TZD add-on to DPP4iSGLT 2i and TZD add-on to DPP4i
02
Targets
DPP-4 (Dipeptidyl Peptidase-IV)PPARG (Peroxisome proliferator-activated receptor gamma)SGLT2 (Sodium-glucose cotransporter protein subunit 2)
Beyond the preview
Go deeper on sitagliptin + dapagliflozin + lobeglitazone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sitagliptin + dapagliflozin + lobeglitazone.